Looks interesting.
Haven’t heard about $ or leadership.
If they blow up the current HAE limited distribution model and grant broader access, they will crush Takeda on that alone.
Well, Takeda’s business is based in the HAE prophylaxis market, not the on demand treatment. Also, the clinical trials don’t show great success rates.Looks interesting.
Haven’t heard about $ or leadership.
If they blow up the current HAE limited distribution model and grant broader access, they will crush Takeda on that alone.